Adam Lustig, MS
Articles
June 19th 2014
The Value of Specialty Pharmaceuticals - A Systematic Review
Martin Zalesak, MD, PhD Joyce S. Greenbaum, BA Joshua T. Cohen, PhD Fotios Kokkotos, PhD Adam Lustig, MS Peter J. Neumann, ScD Daryl Pritchard, PhD Jeffrey Stewart, BA Robert W. Dubois, MD
This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: December 10th 2024 | Updated: January 23rd 2025
Fixed-Duration Acalabrutinib Plus Venetoclax Beats Chemoimmunotherapy in First-Line CLL; Adding Obinutuzumab Boosts PFS
